title: [Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment].
abstract: BACKGROUND
  Due to limited resources within the health service and the continuous discussion on cost containment, economic criteria should also be considered when assessing therapy concepts. Particular results in terms of economic efficiency reserves are to be expected from a transfer of care from the in-patient to the out-patient sector.
  
  
  METHODS
  In a prospective, direct cost recording of all relevant uses of resources, the direct and indirect costs of the treatment of 14 patients with cystic fibrosis (CF) were included in the cross-over-design. The quality of life was recorded at least once for each patient using the EuroQol. In-patient intravenous antibiotic therapy carried out during the block of out-patient care served as one of the disqualification criteria when selecting patients.
  
  
  RESULTS
  Over an observation period of nine months, the average direct cost recorded were DM 35,706 for out-patient and DM 40,143 for in-patient treatment (+15%). As far as indirect costs are concerned, the losses of production in the national economy recorded for in-patient treatment were 80% higher.
  
  
  CONCLUSIONS
  The direct and indirect costs for in-patient CF-therapy are in total higher than for out-patient care. Whether these cost advantages have to be "bought" with lower medical effectiveness needs to be demonstrated by further clinical studies. In the sense of the disease management approach, the results of this study should be used to help rationally weigh up the costs of out-patient care against alternative treatment concepts.
authors.affiliation: Forschungsstelle Gesundheitsökonomie und Gesundheitssystemforschung, Universität Hannover.
authors.forename: J M
authors.initials: JM
authors.lastname: Graf von der Schulenburg
authors.forename: W
authors.initials: W
authors.lastname: Greiner
authors.forename: U
authors.initials: U
authors.lastname: Klettke
authors.forename: U
authors.initials: U
authors.lastname: Wahn
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000191:economics; D005260:Female; D005858:Germany; D018718:Home Infusion Therapy / Q000191:economics*; D006701:Home Nursing / Q000191:economics; D006801:Humans; D008297:Male; D010343:Patient Admission / Q000191:economics*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000191:economics; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000191:economics; D011788:Quality of Life
chemical_list: D000900:Anti-Bacterial Agents